Skip to contentL
Ligand Pharmaceuticals Inc
L
LGNDLigand Pharmaceuticals Inc Q4 2018 · 10-K
Revenue$59.59M$59.59M±0.0% vs Q4 2017 Net Income-$42.48M-$42.48MN/M vs Q4 2017 EPS Diluted-$2.02-$2.02N/M vs Q4 2017 Operating Incomederived$33,149,000+16.9% The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
Operating Cash Flowderived$32,572,000+4.0% Margins · derivedOperating margin55.6%+8.1 pt vs Q4 2017
Net margin-71.3%±0.0 pt vs Q4 2017
ended Dec 31, 2018 · filed Feb 28, 2019 · 59 d after period end